Viral Vector Technologies
Breaking Barriers in Vector Development & Manufacturing
Founded in 2011 in the UK as Oxford Genetics, OXGENE™ was acquired by WuXi AppTec in 2021 and became part of Minaris in 2025 following the merger of Minaris Regenerative Medicine and WuXi Advanced Therapies.
Today, OXGENE™ serves as Minaris’ innovation engine and center of excellence for advanced technologies, including the TESSA® and XOFLX® platforms.
With deep expertise in vector design, plasmids, and cell line development, OXGENE™ complements Minaris’ global CDMO capabilities to deliver integrated solutions that accelerate advanced therapy development.
Where We Make the Difference
SnapFast™ Plasmids
Customizable, high-performance plasmids engineered for optimal expression and yield
TESSA® AAV Production
Helper-virus-free system that increases yield up to 30 times higher compared to triple plasmid transfection across different serotypes
XOFLX® Lentiviral Technology
Stable packaging and producer cell lines for scalable LVV production
HEK293 Cell line
Clonal suspension cell line with DMF to support viral vector manufacturing
Smarter Plasmid Engineering for Viral Vector Development
SnapFast™ plasmids simplify design and speed development with modular, ready-to-use building blocks.
SnapFast™ plasmids, with our experts’ design experience, transform the challenging viral vector production process. SnapFast™ plasmids, featuring modular backbones and a catalog of well-characterized DNA elements, enable the quick and reliable addition of promoters, genes of interest, UTRs, and regulatory features. We design plasmids with the final application in mind, reducing design and construction cycles to build plasmids that perform effectively from discovery through GMP manufacturing.
Why Minaris for Viral Vector Innovation
Minaris leverages OXGENE™ technologies to help move viral vector programs forward. SnapFast™ accelerates plasmid design and optimization, TESSA® improves AAV yield, quality, and cost efficiency, XOFLX® enables scalable, consistent lentiviral vector supply, and the HEK293 Cell Line provides a clonal suspension cell line with a DMF to support scalable AAV and LVV manufacturing. Together, these technologies provide biotech innovators with a reliable path from discovery through clinical development and global commercialization.
With 10+ years of viral vector experience, Minaris integrates OXGENE™’s advanced technologies with robust analytical testing to support AAV and LVV programs at every stage. Our viral vector–focused solutions help reduce development risk, improve process reliability, and accelerate timelines—giving developers greater confidence as they advance complex therapies toward patients.
Explore All
Minaris
Services
intro-section does not exist
Contact Us
Minaris Viral Vectors is dedicated to helping innovators advance complex viral vector programs with confidence. Whether you are in early stage development or preparing for clinical supply, our vector design expertise, process development capabilities, cGMP manufacturing, integrated testing, and commitment to quality make us a trusted partner for scalable viral vector manufacturing from construct to clinic.
